tiprankstipranks
Trending News
More News >
Chiome Bioscience Inc. (JP:4583)
:4583
Japanese Market

Chiome Bioscience Inc. (4583) AI Stock Analysis

Compare
1 Followers

Top Page

JP

Chiome Bioscience Inc.

(4583)

Rating:48Neutral
Price Target:
Chiome Bioscience Inc.'s overall stock score reflects its mixed financial performance, where revenue growth is offset by lack of profitability and negative cash flow. The stock's technical indicators are weak, and the negative P/E ratio makes it less attractive in terms of valuation. The company needs to focus on achieving profitability and improving cash flows to strengthen its financial standing.

Chiome Bioscience Inc. (4583) vs. iShares MSCI Japan ETF (EWJ)

Chiome Bioscience Inc. Business Overview & Revenue Model

Company DescriptionChiome Bioscience Inc. (4583) is a biotechnology company focused on the research, development, and commercialization of therapeutic antibodies. Operating in the pharmaceutical and healthcare sectors, the company leverages its proprietary ADLib system technology to discover novel antibody candidates for various diseases, including cancer and inflammatory conditions. Chiome Bioscience aims to address unmet medical needs by developing innovative antibody-based therapies.
How the Company Makes MoneyChiome Bioscience Inc. generates revenue primarily through the development and commercialization of its therapeutic antibody candidates. The company earns money by licensing its proprietary ADLib system technology to other pharmaceutical companies, enabling them to discover and develop their own antibody products. Additionally, Chiome may receive milestone payments and royalties from partnerships and collaborations with other biotech and pharmaceutical firms. These partnerships often involve co-development agreements where Chiome contributes its expertise in antibody research and development. The company's revenue model is also supported by potential government grants and funding for its research endeavors.

Chiome Bioscience Inc. Financial Statement Overview

Summary
Chiome Bioscience Inc. shows revenue growth but struggles with profitability due to persistent negative net income and EBIT. The company has a strong equity position and low leverage but faces challenges with cash flow, indicating a need for improved operational efficiencies.
Income Statement
45
Neutral
Chiome Bioscience Inc. shows a consistent increase in total revenue over recent years, with a noticeable revenue growth rate of 14.41% from 2023 to 2024. However, the company suffers from persistently negative net income and EBIT, leading to negative net profit margins and EBIT margins. This suggests the company is struggling to convert revenue into profit, a pressing concern for financial health.
Balance Sheet
60
Neutral
The company maintains a strong equity position with an equity ratio of 77.81% in 2024, indicating a solid foundation of stockholders' equity relative to total assets. The debt-to-equity ratio remains low at 0.15, highlighting minimal leverage risk. However, persistent losses and continued reliance on equity financing could pose future sustainability challenges.
Cash Flow
50
Neutral
Chiome Bioscience Inc. exhibits stable operational cash outflows, with operating cash flow improving slightly from 2023 to 2024. However, the free cash flow remains negative, and the free cash flow to net income ratio indicates operational inefficiencies. These aspects highlight challenges in achieving positive cash flow without external financing.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue780.81M682.46M630.82M712.93M480.85M
Gross Profit432.85M398.60M348.86M422.46M245.27M
EBITDA-1.01B-1.21B-1.24B-1.46B-1.29B
Net Income-1.02B-1.22B-1.24B-1.48B-1.29B
Balance Sheet
Total Assets2.47B1.75B2.22B2.34B3.49B
Cash, Cash Equivalents and Short-Term Investments2.06B1.33B1.73B1.79B2.69B
Total Debt281.50M291.00M184.00M183.00M180.00M
Total Liabilities548.55M593.73M424.72M446.39M384.59M
Stockholders Equity1.92B1.16B1.79B1.89B3.11B
Cash Flow
Free Cash Flow-1.00B-1.07B-1.19B-1.13B-1.36B
Operating Cash Flow-1.00B-1.07B-1.19B-1.13B-1.36B
Investing Cash Flow0.00173.00K0.00-35.38M-3.52M
Financing Cash Flow1.74B667.30M1.13B271.35M1.94B

Chiome Bioscience Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price141.00
Price Trends
50DMA
143.84
Negative
100DMA
151.61
Negative
200DMA
161.75
Negative
Market Momentum
MACD
-0.83
Positive
RSI
41.38
Neutral
STOCH
18.52
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4583, the sentiment is Negative. The current price of 141 is below the 20-day moving average (MA) of 150.50, below the 50-day MA of 143.84, and below the 200-day MA of 161.75, indicating a bearish trend. The MACD of -0.83 indicates Positive momentum. The RSI at 41.38 is Neutral, neither overbought nor oversold. The STOCH value of 18.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4583.

Chiome Bioscience Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
¥11.72T28.5922.80%3.51%17.96%25.65%
72
Outperform
$1.16T25.225.34%3.87%6.42%10.82%
67
Neutral
$6.01T20.6717.60%1.86%17.77%49.34%
64
Neutral
¥342.56B10.47-2.86%2.57%11.81%-7.17%
62
Neutral
¥355.58B15.0513.50%26.79%
48
Neutral
¥9.60B
14.41%27.42%
42
Neutral
$21.88B-193.61%179.79%-204.13%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4583
Chiome Bioscience Inc.
141.00
21.00
17.50%
JP:4506
Sumitomo Dainippon Pharma Co
895.00
499.00
126.01%
JP:4519
Chugai Pharmaceutical Co
7,125.00
1,084.07
17.95%
JP:4523
Eisai Co
4,130.00
-2,161.06
-34.35%
JP:4568
Daiichi Sankyo Company
3,223.00
-2,524.73
-43.93%
JP:4563
AnGes
61.00
17.00
38.64%

Chiome Bioscience Inc. Corporate Events

Chiome Bioscience Updates Financial Results for FY 2024
Mar 14, 2025

Chiome Bioscience Inc. has issued corrections to its previously released non-consolidated financial results for the fiscal year ended December 31, 2024. The corrections pertain to minor adjustments in cash flows from operating and financing activities, as well as details in the cost of sales. These adjustments reflect slight changes in financial figures, which may have implications for stakeholders analyzing the company’s financial health and operational efficiency.

Chiome Bioscience and OmniAb Collaborate on Antibody Research
Feb 28, 2025

Chiome Bioscience Inc. has entered a collaborative research agreement with OmniAb, Inc. to explore synergies in bispecific antibody generation. This partnership aims to implement a high throughput screening system, leveraging OmniAb’s OmniClic platform, to enhance Chiome’s antibody development capabilities and strengthen its profitability. The financial impact for the fiscal year ending December 2025 is expected to be minimal.

Chiome Bioscience Reports Modest Sales Growth Amid Continued Financial Challenges
Feb 13, 2025

Chiome Bioscience Inc. reported a modest increase in net sales for the fiscal year 2024, reaching 780 million yen, reflecting a 14.4% rise from the previous year. Despite this growth, the company continues to face financial challenges with significant losses in operating and net income, indicating ongoing struggles within its operations. The financial position improved with an increase in total assets and net assets, showcasing a strengthened equity ratio. The company is cautious about its future financial results, particularly in the drug discovery and development sector, and has only provided forecasts for the drug discovery support business.

Chiome Bioscience’s Tribody™ Technology Shows Promising Results in Cancer Immunotherapy
Feb 12, 2025

Chiome Bioscience Inc. announced the publication of a research paper in collaboration with Ceinge-Biotecnologie Avanzate, highlighting the effectiveness of their Tribody™ technology in cancer immunotherapy. The study demonstrated that their tri-specific Tribody™ antibody could enhance T cell responses more effectively than existing combination therapies by targeting tumor-associated antigens and immune checkpoint molecules. This advancement suggests significant potential for the Tribody™ technology to improve cancer treatment efficacy, potentially impacting the broader biotech and pharmaceutical sectors by reducing the complexity of cancer therapies for patients.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025